The study revealed that patients who after 12-month follow-up developed spondyloarthropathy had statistically lower VEGF levels compared with patients who developed RA, as well as with all the other study populations (those who developed other autoimmune inflammatory conditions or whose arthritis resolved completely). The gene discussed is VEGFA; the disease is arthritic joint disease.